Anthrax toxin

Critical Reviews in Microbiology

Volumn 27, Issue 3, 2001, Pages 167-200

  Bhatnagar, R ^a   Batra, S ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; BACTERIAL ANTIGEN; EDEMA FACTOR; EXOTOXIN; LETHAL TOXIN; PROTECTIVE ANTIGEN; UNCLASSIFIED DRUG;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL VIRULENCE; BACTERIOLOGY; CRYSTALLIZATION; HUMAN; IMMUNITY; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0034805918     PISSN: 1040841X     EISSN: None     Source Type: Journal    
DOI: 10.1080/20014091096738     Document Type: Review

References (196)

1. De attenuation des virus et de leur retour a la virulence
2. Anthrax vaccines: Past, present and future
3. Anthrax toxin
4. On the role of macrophages in anthrax
5. Epidemiology of anthrax in wild animals and the control of anthrax epizootics in the Kruger National Park, South Africa
6. Anthrax epizootics in Etosha National Park
7. Bacillus anthracis on Guinard island
8. Formaldehyde solution effectively inactivates spores of Bacillus anthracis on the Scottish island of Guinard
9. The Sverdlosk anthrax outbreak of 1979
10. Characterization of macrophage sensitivity and resistance to anthrax lethal toxin
11. Anthrax toxin mediated delivery of cytotoxic T cell epitope in vivo
12. Delivery of antigens to the MHC class I pathway using bacterial toxins
13. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp 120-anthrax toxin fusion protein
14. The three Bacillus anthracis toxin genes are coordinately regulated by bicarbonate and temperature
15. Internalization of a Bacillus anthracis protective antigen-c-myc antibodies
16. Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin
17. A major epidemic of anthrax in Zimbabwe
18. Pathology of inhalation anthrax in 42 cases from Sverdlosk outbreak in 1979
19. Field evaluation of human anthrax vaccine
20. Anthrax
21. Anthrax
22. A national register of historic and contemporary anthrax foci
23. Observations on the ocurrence of anthrax as related to soil type and rainfall
24. Anthrax situation in south asian countries in general and Nepal in particular 1997
25. The roles of serum and carbondioxide in capsule formation by Bacillus anthracis
26. Physiochemical examination of polyglutamic acid from Bacillus anthracis grown in vivo
27. Polyglutamic acid from Bacillus anthracis grown in vivo: Structure and aggressin activity
28. Cytology of Bacillus anthracis
29. Comparative ultrastructure of selected aerobic sporeforming bacteria: A freeze-etching study
30. Crystalline surface layers on bacteria
31. Bacillus anthracis S-layer
32. Bacillus anthracis surface: Capsule and S-layer
33. Domain structure of the Acetogenium kivui surface revealed by electron crystallography and sequence analysis
34. Production and cell surface anchoring of functional fusions between the SLH motifs of the Bacillus anthracis S-layer proteins and the Bacillus subtilis levansurase
35. Ecology of anthrax
36. Experimental in the rat. I. The rapid increase of natural resistance observed in young hists
37. Anthrax in the Gambia: A epidemiological study
38. Intestinal anthrax in man: A case report
39. Bacillus
40. Studies on infection with Bacillus anthracis; A histopathological study of skin lesions produced by Bacillus anthracis in susceptible and resistant animal species
41. Observations on experimental anthrax: Demonstration of a specific lethal factor produced in vivo by Bacillus anthracis
42. The chemical basis of virulence of Bacillus anthracis. V. The specific toxin produced by B. anthracis in vivo
43. The chemical basis of virulence of B. anthracis. VII Two components of anthrax toxin: Their relationship to known immunising aggressins
44. Anthrax as a potential biologic warfare agent
45. Anthrax
46. In vivo produced anthrax toxin
47. Anthrax toxin
48. Anthrax toxic complex
49. Contribution of individual toxin components to virulence of Bacillus anthracis
50. Evidence for plasmid mediated toxin production in B. anthracis
51. Demonstration of a capsule plasmid in B. anthracis
52. Association of the encapsulation of B. anthracis with a 60 megadalton plasmid
53. Purification and physical analysis of Bacillus anthracis plasmid pXO1 and pXO2
54. Mapping and characterisation of Bacillus anthracis plasmids pXO1 and pXO2
55. 2 and a trans acting element activate transcription from one of two promoters
56. Cloning and expression of the calmodulin sensitive B. anthracis adenylate cyclase in E. coli
57. Molecular cloning and expression in E. coli of the lethal factor gene of B. anthracis
58. Nucleotide sequence of the B. anthracis edema factor gene: A calmodulin-dependent adenylate cyclase
59. Cloning and characterization of a gene whose product is a transactivator of anthrax toxin synthesis
60. Cloning of the protective antigen gene of B. anthracis
61. Production and purification of anthrax toxin
62. 2 dependant expression of the genetic region for encapsulation from Bacillus anthracis
63. Molecular characteization and protien analysis of the cap region, which is essential for encapsulation in Bacillus anthracis
64. Restriction map of a capsule plasmid of Bacillus anthracis
65. Coordinate regulation and sensory transduction in the control of bacterial virulence
66. Transcriptional regulation of the protective antigen of Bacillus anthracis
67. The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence
68. 2 enhanced non-toxin gene expression in B. anthracis
69. Identification and characterization of a trans activator involved in the regulation of encapsulation by B. anthracis
70. Cross-talk to the genes for Bacillus anthracis capsule synthesis by atxA, the gene encoding the trans-activator of anthrax toxin synthesis
71. Anthrax toxins
72. Autogenous regulation of the Bacillus anthracis pag operon
73. Regulation of pag gene expression in Bacillus anthracis: Use of a pag-lacZ transcriptional fusion
74. Regulation of anthrax toxin activator gene (atxA) expression in Bacillus anthracis: Temperature, not CO2/bicarbonate, affects atx A synthesis
75. Immunity to anthrax. Protective antigen present in cell free filterates
76. Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis
77. The anthrax toxin complex
78. Functional mapping of anthrax toxin lethal factor by in frame insertion mutagenesis
79. Construction and characterization of a protective antigen deficient Bacillus anthracis strain
80. Charaterization of Clostridium perfuringes iota toxin and expression in E. coli
81. Crystal structure of anthrax toxin protective antigen
82. Bacterial toxins
83. Functional characterization of protease treated Bacillus anthracis protective antigen
84. Chymotrypsin sensitive site FFD (315) in anthrax toxin PA is required for translation of lethal factor
85. Anthrax toxin: Channel forming activity of protective antigen in planer phospholipid bilayers
86. A deleted variant of B. anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo
87. Human furin is a calcium dependent serine endoprotease that recognizes the sequence R-X-X-R and efficiently cleaves anthrax toxin protective antigen
88. Macrophages are sensitive to anthrax toxin through an acid dependent process
89. Inhibitors of receptor mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin
90. Protective antigen binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino or carboxy terminus
91. Voltage dependent block of anthrax toxin channels in planer phospholipid bilayer membranes by symmetric tetraalkylammonium ions: Single channel analysis
92. Anthrax toxin protective antigen: Low pH induced hydrophobicity and channel formation in liposomes
93. Adenylate cyclase toxins from B. anthracis and Bordetella pertussis. Different processes for interaction with and entry into target cells
94. pH dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen
95. Cytolytic pore forming proteins and peptides: Is there a common structural motif?
96. Anthrax protective antigen forms oligomers during intoxication of mammalian cells
97. Oligomerization of the anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells
98. The channel formed in planer lipid bilayers by the protective antigen component of anthrax toxin
99. Effect of anthrax toxins lethal factor on ion channels formed by protective antigen
100. The carboxy terminal end of protective antigen is required for receptor binding and anthrax toxin activity
101. Thermostabilization of protective antigen - The binding component of anthrax lethal toxin
102. Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity
103. Immunoelectrophoretic analysis, toxicity and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin
104. Calcium is required for the expression of anthrax lethal toxin activity in the macrophage like cell line J774A. 1
105. Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis
106. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells
107. Residues 1-254 of anthrax toxin lethal factor sufficient to cause cellular uptake of fused polypeptides
108. Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells
109. Site-directed mutagenesis of histidine residues in anthrax toxin lethal factor binding domain reduces toxicity
110. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity
111. Anthrax pathogenesis and host response
112. Zinc content of the Bacillus anthracis lethal factor
113. The cytotoxic activity of Bacillus anthracis lethal factor by leucotrine A4 hydrolase and metallopeptidase inhibitors
114. Biochemical and physiological changes induced by anthrax lethal toxin in J774A.1 macrophage like cells
115. Protein synthesis is required for expression of anthrax lethal toxin cytotoxicity
116. Activation of phospholipase C and protein kinase C is required for expression of anthrax toxin cytotoxicity in J774A.1 cells
117. Mechanism of cell death
118. Role of macrophage oxidative burst in the action of anthrax lethal toxin
119. The vacuolar ATPase pump is required for the cytotoxicity of Bacillus anthracis lethal toxin
120. Lethal factor active site mutations affect catalytic activity in vitro
121. Proteolytic inactvation of MAP-kinase-kinase by anthrax lethal factor
122. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages
123. Signal transduction through MAP kinase cascades
124. Cytoplasmic control of nuclear behaviour during meiotic maturation of frog oocytes
125. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNg- induced release of NO and TNFα
126. Different mitogen activated protein kinase signalling pathways cooperate to regulate tumor necrosis factor alpha gene expression in T lymphocytes
127. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor
128. Cytotoxic effects of anthrax lethal toxin on macrophage-like cell line J774A.1
129. Proteosome activity is required for anthrax lethal toxin to kill macrophages
130. Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis
131. Structural homology between virulence associated bacterial adenylate cyclases
132. Anthrax toxin edema factor: A bacterial adenylate cyclase that increases cAMP conc in eukaryotic cells
133. Construction of Bacillus anthracis mutant strains producing a single toxin component
134. Phagocytic impotence caused by the invasive bacterial adenylate cyclase
135. Effects of anthrax toxin components on human neutrophils
136. Anthrax toxin components stimulate chemotaxis of human polymorphonuclear neutrophils
137. Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide
138. Anthrax edema toxin differentialy regulates lipopolysaccharide induced monocyte production of tumour necrosis factor alpha and interleukin 6 by increasing intracellular cyclic AMP
139. Purification of Factor I and recognition of a third factor of anthrax toxin
140. A-type ATP binding consensus sequences are critical for the catalytic activity of the calmodulin-sensitive adenlyl cyclase from B. anthracis
141. Characterization of a synthetic calmodulin binding peptide derived from Bacillus anthracis adenylate cyclase
142. The chemical basis of virulence of Bacillus anthracis IX its aggressins and their mode of action
143. Recent advances in the development of an improved human anthrax vaccine
144. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells
145. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin
146. Intracellular trafficking and activation of the furin proprotein convertase: Localization to the TGN and recycling to the cell surface
147. Interaction of protective antigen with membranes
148. The cytoplasmic domain of the diphtheria toxin receptor (HB-EGF precursor) is not required for receptor-mediated endocytosis
149. Characterization of membrane translocation by anthrax protective antigen
150. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell
151. Large-scale production of protective antigen of B. anthracis anaerobic cultures
152. Production of Bacillus anthracis antigens in a new defined culture media
153. Quantitation assay for crude anthrax toxins
154. Purifications of factors I and II of the anthrax toxin produced in vivo
155. Production in vitro of the toxin of B. anthracis previosly recognized in vivo
156. Production of toxin in vitro by Bacillus anthracis and its separation into two components
157. Purification of anthrax toxin components by high performance anion-exchange, gel filtration and hydrophobic interaction chromatography
158. Separation of three exotoxic factors of B. anthracis by sequential immunoadsorbent chromatography
159. Cloning and expression of the B. anthracis protective antigen gene in B. subtilis
160. Construction of a Bacillus subtilis double mutant deficient in extracellular alkaline and neutral proteases
161. Development of a novel Bacillus subtilis cloning system employing its neutral protease as screen marker
162. The structure of neutral protease from Bacillus cereus at 0.2 nm resolution
163. Fermentation, purification and characterization of protective antigen from a recombinant, avirulent strain of B. anthracis
164. Expression of Bacillus anthracis protective antigen by baculovirus and vaccinia virus recombinants
165. Expression and purification of the recombinant protective antigen of B. anthracis
166. Expression and purification of the recombinant lethal factor of Bacillus anthracis
167. Optimized production and purification of Bacillus anthracis lethal factor
168. Development of novel vaccines against anthrax in man
169. Distribution and economic importance of anthrax
170. The use of anthrax vaccine prepared from avirulent (uncapsulated) variants of B. anthracis
171. The effects of different carbondioxide concentrations on the growth of virulent anthrax strains. Pathogenicity and immunity tests on guinea-pigs and sheep with anthrax variants derived from virulent strains
172. Anthrax: The disease in relation to vaccines
173. Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man
174. Thoroughly modern anthrax
175. Studies on a protective antigen produced in vitro from Bacillus anthracis: Medium and methods of production
176. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey
177. Anthrax toxin: Causative agent in the death of Rhesus monkeys
178. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of B. anthracis using monoclonal antibodies
179. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis
180. Production and characterization of monoclonal antibodies to the protective antigen component of B. anthracis
181. Structure function analysis of Bacillus anthracis edema factor by using monoclonal antibodies
182. Experimental anthrax vaccines: Efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs
183. Protective immunity induced by B. anthracis toxin deficient strains
184. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants
185. Protection conferred by microbially supplemented UK and purified PA vaccines
186. Efficacy of the UK human anthrax vaccine in guinea pigs against aerosolized spores of Bacillus anthracis
187. A new immunomodulator with potential clinical applications: Monophosphoryl lipid A, a detoxified endotoxin
188. Immunization against anthrax with aromatic compound dependent (Aro) mutants of Bacillus anthracis and with the recombinant strains of Bacillus subtilis that produce anthrax protective antigen
189. Bacillus anthracis protective antigen expressed in Salmonella typhimurium SL3261, affords protection against anthrax spore challenge
190. Expression of the protective antigen of Bacillus anthracis by Lactobacillus strains: Towards the development of an oral vaccine against anthrax
191. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen
192. Presentation of protective antigen to the mouse immune system: Immune sequelae